8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2010

Shire plc

________________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands

________________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0601486

(Commission File Number)                (IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin

24, Republic of Ireland

________________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               +353 1 429 7700

________________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))

Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Agreements of Certain Officers.

    The Board of Directors of Shire plc (“Shire”) announced on June 17, 2010 that Dr David Ginsburg and Ms Anne Minto OBE will join the Board of Directors as Non Executive Directors with immediate effect. Dr David Ginsburg has been appointed to Shire's Science & Technology Committee and Ms Anne Minto will be a member of Shire’s Remuneration Committee and will assume the Chair of that Committee at the end of July 2010. Shire has issued the press release attached as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01.   Financial Statements and Exhibits

(d)  Exhibits.  The following exhibit is filed herewith:

99.01          Press Release dated June 17, 2010

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant  has duly caused  this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ A C Russell
	Name:	Angus Russell
	Title:	Chief Executive Officer

Dated: June 17, 2010

EXHIBIT INDEX
Number	Description
99.01	Press Release dated June 17, 2010

EX-99.1

Exhibit 99.01

Press Release
www.shire.com

Two New Board Directors Appointed

Non-Executives to join Shire’s Science &Technology and Remuneration Committees

Dublin, Ireland – June 17, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that Dr David Ginsburg and Ms Anne Minto OBE, have been appointed to the Shire Board of Directors with immediate effect.

Dr Ginsburg, MD is currently Professor of Internal Medicine & Human Genetics at the Life Sciences Institute, University of Michigan; an Investigator at the Howard Hughes Medical Institute and the Warner-Lambert/Parke-Davis Professor of Medicine.  

Dr Ginsburg qualified at Yale University and has a very distinguished background that includes many research achievements, fellowships, awards and published papers. These have included a research post at Harvard Medical School and numerous senior professorial positions across a broad spectrum of medical specializms at the University of Michigan.  Dr Ginsburg has also been appointed to Shire’s Science & Technology Committee.

Anne Minto is Group Director Human Resources at Centrica plc, a FTSE 30 integrated energy company operating in the UK and US. Ms Minto qualified as a lawyer at Aberdeen University and has an impressive business career that includes senior roles at Shell UK and Smiths Group plc and the position of deputy director-general of the Engineering Employers’ Federation. 

Ms Minto is a Fellow of both the Chartered Institute of Personnel & Development and the London City and Guilds and a Member of Law Society of Scotland.  Anne Minto has also been appointed to Shire’s Remuneration Committee and she will assume the Chair of that Committee on the retirement of Kate Nealon from the Shire Board at the end of Ms Nealon’s term of office at the end of July.

Shire Chairman, Matthew Emmens commented:  “I am very pleased that we have attracted two highly qualified and experienced Directors to our Board.  David’s medical background and areas of specializm and Anne’s legal, commercial and remuneration experience will be welcome additions to our strong team.  I’d like to thank Kate Nealon for her four years of service to Shire’s Board and for her contributions to the Remuneration Committee.”

There is no further information that is required to be disclosed under 9.6.13R of the United Kingdom listing rules

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 781 482 0999
Media	Jessica Mann (Rest of the World)	+44 1256 894 280
	Matthew Cabrey (North America, Specialty Pharma)	+1 484 595 8248

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company’s Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company’s products; the Company’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company’s products; the Company’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission.